Open AccessCost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
Author(s) -
Claire Telford,
Evelina Bertranou,
Samuel Large,
Hilary Phelps,
Mattias Ekman,
C. Livings
Publication year - 2019
Publication title -
pharmacoeconomics - open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 10
eISSN - 2509-4254
pISSN - 2509-4262
DOI - 10.1007/s41669-019-0134-3
Subject(s) - fulvestrant , anastrozole , letrozole , medicine , tamoxifen , oncology , breast cancer , metastatic breast cancer , gynecology , quality adjusted life year , cancer , cost effectiveness , risk analysis (engineering)
The selective estrogen receptor degrader fulvestrant is approved for the first-line treatment of postmenopausal patients with hormone receptor-positive (HR+), locally advanced or metastatic breast cancer who have not received prior endocrine therapy. We evaluated the cost-effectiveness of fulvestrant versus comparator treatments in endocrine therapy-naïve patients with locally advanced or metastatic breast cancer.